Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs known as pharmacological chaperones. We are developing pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders. Our development programs include novel small molecules as monotherapy treatments and in combination with the current standard of treatment for Fabry and other lysosomal storage diseases, enzyme replacement therapy (ERT). Our Chaperone-Advanced Replacement Therapy, or CHART, programs include chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with our pharmacological chaperones as next-generation ERTs. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-1.08 |
| Quarterly EPS Est: | -0.32 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
1.86 |
Data is provided by Zacks Investment Research

